Successful treatment of a chemo-resistant gestational trophoblastic neoplasia using GEMOX. Clinical case

A. A. Meshcheryakov; Мещеряков А. А.; T. E. Tikhomirova; Тихомирова Т. Е.; L. A. Meshcheryakova; Мещерякова Л. А.

doi:10.18821/1028-9984-2020-25-1-42-46

Successful treatment of a chemo-resistant gestational trophoblastic neoplasia using GEMOX. Clinical case

Authors: Meshcheryakov A.A.¹, Tikhomirova T.E.¹, Meshcheryakova L.A.¹
Affiliations:
1. N.N. Blokhin Cancer Research Center
Issue: Vol 25, No 1 (2020)
Pages: 42-46
Section: Case Reports
URL: https://rjonco.com/1028-9984/article/view/35119
DOI: https://doi.org/10.18821/1028-9984-2020-25-1-42-46
ID: 35119

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Gestational trophoblastic neoplasia is a rare malignancy. The main treatment approach is chemotherapy. Almost all patients can be cured if the diagnosis is established timely and adequate treatment is provided in specialized centers.

In a small part of patients, the tumor progresses despite the use of all standard chemotherapy regimens. Treatment of such patients is difficult for all oncologists, including ones working in specialized centers for the treatment of gestational trophoblastic neoplasia.

This article presents a clinical case of the successful treatment of a patient with multidrug resistant gestational trophoblastic neoplasia using GEMOX regimen.

Keywords

gestational trophoblastic neoplasia, gestational trophoblastic disease, resistance, high-risk gestational trophoblastic neoplasia, gemcitabine, oxaliplatin

Full Text

References

Meshcheryakova L.A. Standard treatment for trophoblastic disease. Pract. Oncol. 2008; 9 (3): 160–70. (in Russian)
Meshcheryakova L.A. Trophoblastic disease. Opukholi zhenskoy reproducrivnoy sistemy. 2014; 4 (74–82). (in Russian)
Kim S.J., Bae S.N., Kim J.H., Kim C.J., Jung J.K. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol. 1998; 71: 247–53.
Abdulaziz B., Brent J., Prafull Gh. Management of EMA-CO resistant/refractory gestational trophoblastic neoplasia. Cancer Rep. Rev. 2019; 3: 1–8.
Lurain J.R., Schink J.C. Importance of salvage therapy in the management of highrisk gestational trophoblastic neoplasia. J. Reprod. Med. 2012; 57: 219–24.
Newlands E.S. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Bailliere’s Best Pract. Res. Clin. Obstet. Gynaecol. 2003; 17: 905–23.
Lurain J. Treatment of gestational trophoblastic tumors. Curr. Treat Options Oncol. 2002; 3: 113–24.
Xiang Y., Sun Z., Wan X. et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J. Reprod. Med. 2004; 49: 443Y446.
Newlands E.S., Mulholland P.J., Holden L. et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J. Clin. Oncol. 2000; 18: 854–9.
Wang J., Short D., Sebire N.J., Lindsay I., Newlands E.S. et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/ etoposide (TP/TE). Ann. Oncol. 2008; 19: 1578–83.
Lurain J.R., Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol. Oncol. 2005; 97: 618–23.
Termrungruanglert W., Kudelka A.P., Piamsomboon S. et al. Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs. 1996; 7: 503.
Popadiuk C., Power P. Pegylated Liposomal Doxorubicin Is an Active Agent for Chemotherapy-Resistant Choriocarcinoma: A Report of Two Cases. J. Reprod. Med. 2016; 61: 215.
Bianconi M., Jankilevich G., Otero S. et al. Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol. Oncol. 2007; 106: 268.
Pandian Z., Seckl M.J., Smith R., Lees D.A. Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery. BJOG. 2004; 111 (4): 382–4.
Worley M.J. Jr, Elias K.M., Horowitz N.S. et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Gynecol. Oncol. 2018; 148: 5.
Ghorani E., Kaur B., Fisher R.A., Short D., Joneborg U. et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017; 390: 2343–5.
Huang M., Pinto A., Castillo R.P., Slomovitz B.M. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J. Clin. Oncol. 2017; 35 (27): 3172–4.
Avelumab in chemo-resistant gestational trophoblastic neoplasias (TROPHIMMUN). Available at: http://clinicaltrials.gov/ct2/show/NCT03135769 (Accessed 30 July 2019).
Tempero M., Plunkett W., RuizVan Haperen V. et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 2003; 21: 3402–8.
Louvet C., Labianca R., Hammel P. et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. J. Clin. Oncol. 2005; 23: 3509–16. © 2005 by American Society of Clinical Oncology.
Andre´ T., Tournigand C., Rosmorduc O. et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals of Oncology. 2004; 15: 1339–43.
Faivre S., Raymond J.M., Woynarowski J.M. et al. Suppra additive effect of 20, 20 -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol. 1999; 44 (2): 117–23.